EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Prophylactic intravenous tranexamic acid and thromboembolism in non‐cardiac surgery: a systematic review, meta‐analysis and trial sequential analysis

S E H Tsan iD, N L Viknaswaran, C C Cheong, S Cheah, K T Ng, S X Y Mong, C Y Wang

Anaesthesia · 2023-09 · 78 (9) · 1153-1161

DOI: 10.1111/anae.16058 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Anaesthesia, online erschienen am 14.06.2023. Verfasst von S E H Tsan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology and Intensive Care, Faculty of Medicine and Health Sciences, University of Malaysia Sarawak, Malaysia. Hauptthemen laut MEDLINE: Tranexamic Acid, Antifibrinolytic Agents, Thromboembolism, Myocardial Infarction. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects. We aimed to investigate the effect of prophylactic intravenous tranexamic acid on thromboembolic outcomes in patients undergoing non‐cardiac surgery. The MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials were searched. Randomised controlled trials comparing intravenous tranexamic acid with placebo or no treatment in patients undergoing non‐cardiac surgery were included. The primary outcome was a composite of peri‐operative cardiovascular thromboembolic events, defined as any deep vein thrombosis, pulmonary embolism, myocardial ischaemia/infarction or cerebral ischaemia/infarction. A total of 191 randomised controlled trials (40,621 patients) were included in the review. The primary outcome occurred in 4.5% of patients receiving intravenous tranexamic acid compared with 4.9% of patients in the control group. Our analysis showed that there was no difference between groups for composite cardiovascular thromboembolic events (risk ratio 1.02, 95%CI 0.94–1.11, p = 0.65, I 2 0%, n = 37,512). This finding remained robust when sensitivity analysis was performed with continuity correction and in studies with a low risk of bias. However, in trial sequential analysis, our meta‐analysis only achieved 64.6% of the required information size. There was no association between intravenous tranexamic acid and seizure rate or mortality rate within 30 days. Intravenous tranexamic acid was associated with a reduced blood transfusion rate compared with control (9.9% vs. 19.4%, risk ratio 0.46, 95%CI 0.41–0.51, p < 0.0001). It was encouraging to see the evidence that the administration of intravenous tranexamic in patients undergoing non‐cardiac surgery was not associated with an increased risk of thromboembolic outcomes. However, our trial sequential analysis demonstrated that currently available evidence is not yet sufficient to reach a firm conclusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidAntifibrinolytic AgentsThromboembolismMyocardial InfarctionHumansBlood TransfusionBlood Loss, Surgical

Stichwörter der Autor:innen

non-cardiac surgerysafetythromboembolismtranexamic acid

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Anaesthesiology and Intensive Care, Faculty of Medicine and Health Sciences, University of Malaysia Sarawak, Malaysia.
  • Department of Medicine, Victoria Hospital, Kirkcaldy, UK.
  • Department of Anaesthesia, Faculty of Medicine, University of Malaya, Malaysia.
  • Department of Anaesthesiology and Intensive Care, Hospital Sultanah Nora Ismail, Batu Pahat, Malaysia.
  • Department of Anaesthesiology and Intensive Care, Hospital Raja Permaisuri Bainun, Ipoh, Malaysia.

ORCID-Profile: S E H Tsan

Zitieren

APA

Tsan, S. E. H., Viknaswaran, N. L., Cheong, C. C., Cheah, S., Ng, K. T., Mong, S. X. Y., & Wang, C. Y. (2023). Prophylactic intravenous tranexamic acid and thromboembolism in non‐cardiac surgery: a systematic review, meta‐analysis and trial sequential analysis. Anaesthesia, 78(9), 1153-1161. https://doi.org/10.1111/anae.16058

Vancouver

Tsan SEH, Viknaswaran NL, Cheong CC, Cheah S, Ng KT, Mong SXY, et al. Prophylactic intravenous tranexamic acid and thromboembolism in non‐cardiac surgery: a systematic review, meta‐analysis and trial sequential analysis. Anaesthesia. 2023;78(9):1153-1161. doi:10.1111/anae.16058

BibTeX
@article{Tsan2023,
  author = {Tsan, S E H and Viknaswaran, N L and Cheong, C C and Cheah, S and Ng, K T and Mong, S X Y and Wang, C Y},
  title = {Prophylactic intravenous tranexamic acid and thromboembolism in non‐cardiac surgery: a systematic review, meta‐analysis and trial sequential analysis},
  journal = {Anaesthesia},
  year = {2023},
  volume = {78},
  number = {9},
  pages = {1153--1161},
  doi = {10.1111/anae.16058}
}
Kostenlos starten →